Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial
Top Cited Papers
- 1 September 2001
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 358 (9285) , 866-869
- https://doi.org/10.1016/s0140-6736(01)06068-8
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190Journal of Clinical Oncology, 2000
- Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastasesThe Lancet, 1998
- Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.Journal of Clinical Oncology, 1998
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- Results of adjuvant interferon study In WHO melanoma programmeThe Lancet, 1994
- Phase II study of recombinant leukocyte a interferon (rIFN-αA) in disseminated malignant melanomaCancer, 1984
- A Randomized Trial of Adjuvant Chemotherapy and Immunotherapy in Cutaneous MelanomaNew England Journal of Medicine, 1982
- Adjuvant Immunotherapy or Chemotherapy for Malignant Melanoma: Preliminary Report of the National Cancer Institute Randomized Clinical TrialSurgical Clinics of North America, 1981
- Adjuvant Therapy for Malignant MelanomaSurgical Clinics of North America, 1981
- A Multifactorial Analysis of MelanomaAnnals of Surgery, 1981